Phase II Dose-Ranging Study of the Efficacy and Safety of Oglemilast in Patients With COPD [chronic obstructive pulmonary disease].

Trial Profile

Phase II Dose-Ranging Study of the Efficacy and Safety of Oglemilast in Patients With COPD [chronic obstructive pulmonary disease].

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2012

At a glance

  • Drugs Oglemilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Aug 2009 Results reported in a Forest Laboratories/Glenmark Pharmaceuticals media release.
    • 29 May 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 29 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top